255 related articles for article (PubMed ID: 24401277)
21. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
[TBL] [Abstract][Full Text] [Related]
22. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays.
Verma A; Ngundi MM; Meade BD; De Pascalis R; Elkins KL; Burns DL
Clin Vaccine Immunol; 2009 Oct; 16(10):1405-12. PubMed ID: 19656993
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
25. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
26. Fcγ receptor pathways during active and passive immunization.
Bournazos S; Ravetch JV
Immunol Rev; 2015 Nov; 268(1):88-103. PubMed ID: 26497515
[TBL] [Abstract][Full Text] [Related]
27. A requirement for FcγR in antibody-mediated bacterial toxin neutralization.
Abboud N; Chow SK; Saylor C; Janda A; Ravetch JV; Scharff MD; Casadevall A
J Exp Med; 2010 Oct; 207(11):2395-405. PubMed ID: 20921285
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
Kelly-Cirino CD; Mantis NJ
Infect Immun; 2009 Nov; 77(11):4859-67. PubMed ID: 19703971
[TBL] [Abstract][Full Text] [Related]
29. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
[TBL] [Abstract][Full Text] [Related]
30. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.
DiLillo DJ; Palese P; Wilson PC; Ravetch JV
J Clin Invest; 2016 Feb; 126(2):605-10. PubMed ID: 26731473
[TBL] [Abstract][Full Text] [Related]
31. Affinity of human IgG subclasses to mouse Fc gamma receptors.
Dekkers G; Bentlage AEH; Stegmann TC; Howie HL; Lissenberg-Thunnissen S; Zimring J; Rispens T; Vidarsson G
MAbs; 2017 Jul; 9(5):767-773. PubMed ID: 28463043
[TBL] [Abstract][Full Text] [Related]
32. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.
Winterroth L; Rivera J; Nakouzi AS; Dadachova E; Casadevall A
Infect Immun; 2010 Jun; 78(6):2890-8. PubMed ID: 20385755
[TBL] [Abstract][Full Text] [Related]
34. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
[TBL] [Abstract][Full Text] [Related]
35. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.
Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME
MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295
[TBL] [Abstract][Full Text] [Related]
36. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.
Nimmerjahn F; Gordan S; Lux A
Trends Immunol; 2015 Jun; 36(6):325-36. PubMed ID: 25981969
[TBL] [Abstract][Full Text] [Related]
37. A homogeneous bioluminescent immunoassay for parallel characterization of binding between a panel of antibodies and a family of Fcγ receptors.
Nath N; Godat B; Flemming R; Urh M
Sci Rep; 2022 Jul; 12(1):12185. PubMed ID: 35842448
[TBL] [Abstract][Full Text] [Related]
38. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
39. Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen.
Verma A; Ngundi MM; Price GA; Takeda K; Yu J; Burns DL
mBio; 2018 Feb; 9(1):. PubMed ID: 29487236
[TBL] [Abstract][Full Text] [Related]
40. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
Yu X; Menard M; Prechl J; Bhakta V; Sheffield WP; Lazarus AH
Blood; 2016 Jan; 127(1):132-8. PubMed ID: 26500340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
